WASHINGTON — Recent disclosures from Securities and Exchange Commission filings reveal that the “most-favored nation” drug pricing agreements established during the Trump administration will expire after three years for certain pharmaceutical companies. While these deals were touted as a means to ensure the U.S. does not overpay for prescription drugs, the specifics surrounding their implementation and duration have largely remained opaque.
The implications of these agreements are significant for the pharmaceutical landscape, as they were designed to align U.S. drug prices with those in other countries, potentially reshaping market dynamics. As these deals come to an end, companies will need to reassess their pricing strategies and market positioning in a landscape that may revert to previous pricing norms. This shift could influence negotiations with payers and impact overall drug affordability in the U.S.
Use the database as your supply chain compass →
